Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer - Li, X; Yang, C; Wan, H (Eur J Pharm Sci, 2017)